2025-05-11 - Analysis Report
## Merck & Co Inc (MRK) Stock Analysis Report

**0. Summary Statistics:**

* **Ticker:** MRK
* **Company:** Merck & Co Inc, a leading pharmaceutical company.
* **Cumulative Return (MRK):** 17.41%
* **Cumulative Return (VOO):** 87.98%
* **Return Difference (MRK vs VOO):** -70.6%
* **Relative Divergence Rank:** 9.3% (meaning its performance is at the 9.3rd percentile relative to its historical performance compared to VOO)


**1. Performance Comparison & Alpha/Beta Analysis:**

Merck's cumulative return significantly underperformed the S&P 500 (VOO) over the period analyzed.  The provided data shows a substantial negative divergence. The historical alpha and beta values fluctuate, indicating varying levels of market sensitivity and outperformance.  Note that the CAGR (Compound Annual Growth Rate) and Maximum Drawdown (MDD) figures  illustrate the volatility and potential risk associated with MRK's past performance.  Higher alpha values suggest better risk-adjusted returns compared to the market.  High beta implies higher volatility compared to the market. The significant negative alpha in the recent periods is of concern.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 10.0% | 58.6% | -22.0% | 0.1 | 106.0 |
| 2016-2018  | 49.0% | 66.4% | 27.0% | 0.4 | 148.3 |
| 2017-2019  | 48.0% | 66.4% | 14.0% | 0.9 | 181.4 |
| 2018-2020  | 26.0% | 66.4% | -4.0% | 0.7 | 168.3 |
| 2019-2021  | 4.0% | 65.6% | -56.0% | 0.5 | 171.3 |
| 2020-2022  | 20.0% | 69.3% | 11.0% | 0.5 | 255.9 |
| 2021-2023  | 43.0% | 69.3% | 22.0% | 0.3 | 258.5 |
| 2022-2024  | -3.0% | 69.3% | -24.0% | 0.2 | 242.3 |
| 2023-2025  | -52.0% | 70.2% | -78.0% | 0.2 | 190.8 |


**2. Recent Price Movement:**

* **Closing Price:** $77.65
* **Last Market Price:** $75.97 (a decrease of $2.16)
* **5-Day Moving Average:** $80.37
* **20-Day Moving Average:** $80.25
* **60-Day Moving Average:** $86.20

The stock price is currently below all three moving averages, suggesting a downward trend.  The recent price drop is significant.

**3. Technical Indicators & Expected Return:**

* **Market Risk Indicator (MRI):** 0.37 (Medium Risk)
* **RSI:** 48.88 (Slightly below neutral; not significantly oversold)
* **PPO:** 0.06 (Positive, but low; suggesting weak momentum)
* **20-Day Relative Divergence Change:** -9.9% (Short-term bearish trend)
* **Expected Return (vs S&P 500, long-term):** -41.7% (This suggests significant underperformance compared to the S&P 500 over the long term,  assuming the forecast is accurate. This is a crucial area requiring further examination.)


**4. Recent Earnings Analysis:**

The earnings data shows some volatility in both EPS and revenue. There's a need for further investigation into the reasons behind the fluctuations. The last data point is duplicated in the table, which needs to be clarified.

| Date       | EPS  | Revenue      |
|------------|------|---------------|
| 2025-05-02 | 2.01 | $15.53 B      |
| 2024-11-06 | 1.25 | $16.66 B      |
| 2024-08-05 | 2.15 | $16.11 B      |
| 2024-05-03 | 1.88 | $15.78 B      |
| 2025-05-02 | 1.88 | $15.78 B      |


**5. Financial Information:**

The financial data indicates relatively stable revenue but some fluctuation in profitability metrics (Profit Margin and ROE). The high profit margins are positive, but the inconsistency in ROE needs further analysis to understand the underlying drivers.

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-03-31 | $15.53B | 77.98% |
| 2024-12-31 | $15.62B | 75.50% |
| 2024-09-30 | $16.66B | 75.51% |
| 2024-06-30 | $16.11B | 76.76% |
| 2024-03-31 | $15.78B | 77.56% |


**Capital and Profitability:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-03-31 | $48.34B | 10.51% |
| 2024-12-31 | $46.31B | 8.08% |
| 2024-09-30 | $44.50B | 7.09% |
| 2024-06-30 | $43.58B | 12.52% |
| 2024-03-31 | $40.36B | 11.80% |



**6. Overall Analysis:**

Merck's performance has significantly lagged the S&P 500, as evidenced by both cumulative returns and the long-term expected return forecast. While the company exhibits high profit margins, recent earnings and price action indicate a downward trend.  The negative alpha in recent years is a serious concern. The current technical indicators do not point towards a strong buying signal.  Further investigation is needed to understand the reasons for the underperformance, including a review of the company's strategic direction, competitive landscape, and any potential upcoming catalysts. The provided -41.7% long-term expected return is a significant negative factor that warrants detailed scrutiny and possibly a reassessment of the underlying assumptions in that projection.  The duplicated data points in the earnings data need clarification.  Before making any investment decisions, it's crucial to conduct thorough due diligence and potentially consult with a financial advisor.
